EUVIMEDEUVIMED entdecken
Crossref

Frequencies and mechanisms of mutational resistance to ceftibuten/avibactam in Enterobacterales

Shazad Mushtaq iD, Anna Vickers, Michel Doumith, Paolo Garello, Neil Woodford, David M Livermore

Journal of Antimicrobial Chemotherapy · 03.03.2025 · 80 (3) · 645-656

DOI: 10.1093/jac/dkae452 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Antimicrobial Chemotherapy, online erschienen am 12.12.2024. Verfasst von Shazad Mushtaq und 5 weiteren Autor:innen. Beteiligte Einrichtung: Antimicrobial Resistance and Healthcare Associated Infections Reference Unit, UK Health Security Agency, London, UK. Hauptthemen laut MEDLINE: Azabicyclo Compounds, Anti-Bacterial Agents, Enterobacteriaceae, beta-Lactamase Inhibitors. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 33 Literaturangaben. Gefördert von: Pfizer.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Antibiotic resistance complicates treatment of urinary infections, particularly when these ascend above the bladder, with few oral options remaining. New oral β-lactamase inhibitor combinations present a potential answer, with ceftibuten/avibactam—now undergoing clinical trials—widely active against strains with ESBLs and serine carbapenemases. To inform its development we undertook mutant selection studies.

Methods

Single-step mutants were sought from Enterobacterales (n = 24) with AmpC, ESBL, OXA-48 and KPC β-lactamases. MICs were determined by CLSI agar dilution. Illumina WGS of selected mutants (n = 50) was performed.

Results

Even at low MIC multiples, mutant frequencies were mostly only c. 10−8. β-Lactamase structural mutants were obtained only from KPC and AmpC enzymes. The KPC mutants had Trp105Arg or Ser130Thr substitutions, causing only small MIC shifts; the AmpC mutant had an Asn346Trp replacement, as previously selected with other avibactam combinations. No ESBL mutants were obtained. Rather, from Escherichia coli, we predominantly selected mutants with modifications to ftsI, encoding penicillin-binding protein (PBP) 3. From Klebsiella pneumoniae and Enterobacter cloacae we predominantly obtained variants with modification of uptake and efflux components or their regulators. ftsI mutants lacked cross-resistance to other avibactam combinations; uptake mutants had broader MIC rises. A few putative mutants had other lesion(s) of uncertain significance, or grew as small, stressed colonies lacking detectable lesions.

Conclusions

There seems little risk of ESBLs mutating to confer ceftibuten/avibactam resistance, though some risk may apply for KPC and AmpC enzymes. The propensity to select E. coli ftsI/PBP3 mutants is notable and was not seen with other avibactam combinations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Azabicyclo CompoundsAnti-Bacterial AgentsEnterobacteriaceaebeta-Lactamase InhibitorsCephalosporinsMicrobial Sensitivity Testsbeta-LactamasesDrug CombinationsHumansBacterial ProteinsWhole Genome SequencingMutationMutation Rate

Substanzen

Azabicyclo Compoundsbeta-LactamasesAnti-Bacterial AgentsDrug CombinationsBacterial Proteinsbeta-Lactamase InhibitorsCephalosporinsavibactam

Autor:innen und Institutionen

  • Antimicrobial Resistance and Healthcare Associated Infections Reference Unit, UK Health Security Agency, London, UK.
  • STI Reference Laboratory, UK Health Security Agency, London, UK.
  • Norwich Medical School, University of East Anglia, Floor 2, Bob Champion Research & Educational Building, James Watson Road, Norwich NR4 7UQ, UK.

ORCID-Profile: Shazad Mushtaq

Förderung

  • Pfizer

Zitieren

APA

Mushtaq, S., Vickers, A., Doumith, M., Garello, P., Woodford, N., & Livermore, D. M. (2025). Frequencies and mechanisms of mutational resistance to ceftibuten/avibactam in Enterobacterales. Journal of Antimicrobial Chemotherapy, 80(3), 645-656. https://doi.org/10.1093/jac/dkae452

Vancouver

Mushtaq S, Vickers A, Doumith M, Garello P, Woodford N, Livermore DM. Frequencies and mechanisms of mutational resistance to ceftibuten/avibactam in Enterobacterales. Journal of Antimicrobial Chemotherapy. 2025;80(3):645-656. doi:10.1093/jac/dkae452

BibTeX
@article{Mushtaq2025,
  author = {Mushtaq, Shazad and Vickers, Anna and Doumith, Michel and Garello, Paolo and Woodford, Neil and Livermore, David M},
  title = {Frequencies and mechanisms of mutational resistance to ceftibuten/avibactam in Enterobacterales},
  journal = {Journal of Antimicrobial Chemotherapy},
  year = {2025},
  volume = {80},
  number = {3},
  pages = {645--656},
  doi = {10.1093/jac/dkae452}
}
Kostenlos starten →